Published by Benjamin Chiou on 12th November 2026
(Sharecast News) - Life sciences investor Syncona reported a 3% increase in net asset value per share in the first half, driven by positive clinical trial results from portfolio company Beacon Therapeutics, as it reiterated plans to return at least £250m to shareholders.
URL: http://www.digitallook.com/dl/news/story/36347229/...